Abstract
Dysregulation of coagulation and fibrinolytic factors is now being recognized as not just a late-stage sequelae of liver disease, but in fact one of the potential contributing risk factors for liver cirrhosis. Recent molecular and animal studies have uncovered intriguing roles for plasmin and the plasminogen activators in protecting the liver from fibrosis development in a manner that is largely fibrin-independent. These pleiotropic effects may be explained by functions of their other proteolytic targets (e.g. hepatocyte growth factor) and receptor-mediated signaling. This review features salient basic science research which shows the immense potential of promoting the hepatic activity of plasmin and its activators in the prevention and treatment of liver cirrhosis in humans.
Keywords: Fibrinolysis, hepatic stellate cell, hepatocyte growth factor, liver fibrosis, plasminogen, plasminogen activator inhibitor-1, tissue-type plasminogen activator, urokinase plasminogen activator, fibrinolytic factors, hepatocyte growth factor), coagulation cascade, Pro-fibrotic cytokines, extracellular matrix components, coagulation factors, carbon tetrachloride
Current Pharmaceutical Biotechnology
Title: Fibrinolytic Factors in Liver Fibrosis
Volume: 12 Issue: 9
Author(s): Liang-I Kang and Wendy M. Mars
Affiliation:
Keywords: Fibrinolysis, hepatic stellate cell, hepatocyte growth factor, liver fibrosis, plasminogen, plasminogen activator inhibitor-1, tissue-type plasminogen activator, urokinase plasminogen activator, fibrinolytic factors, hepatocyte growth factor), coagulation cascade, Pro-fibrotic cytokines, extracellular matrix components, coagulation factors, carbon tetrachloride
Abstract: Dysregulation of coagulation and fibrinolytic factors is now being recognized as not just a late-stage sequelae of liver disease, but in fact one of the potential contributing risk factors for liver cirrhosis. Recent molecular and animal studies have uncovered intriguing roles for plasmin and the plasminogen activators in protecting the liver from fibrosis development in a manner that is largely fibrin-independent. These pleiotropic effects may be explained by functions of their other proteolytic targets (e.g. hepatocyte growth factor) and receptor-mediated signaling. This review features salient basic science research which shows the immense potential of promoting the hepatic activity of plasmin and its activators in the prevention and treatment of liver cirrhosis in humans.
Export Options
About this article
Cite this article as:
Kang Liang-I and M. Mars Wendy, Fibrinolytic Factors in Liver Fibrosis, Current Pharmaceutical Biotechnology 2011; 12 (9) . https://dx.doi.org/10.2174/138920111798281036
DOI https://dx.doi.org/10.2174/138920111798281036 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peptidomics Biomarker Discovery in Mouse Models of Obesity and Type 2 Diabetes
Combinatorial Chemistry & High Throughput Screening Nitric Oxide-Mediated Endothelial Dysfunction - Is there Need to Treat?
Current Vascular Pharmacology Efficacy of Enzyme Replacement Therapy in Fabry Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents VEGF Signal System: The Application of Antiangiogenesis
Current Medicinal Chemistry Mitochondria-Targeted Antioxidant Peptide SS31 Protects the Retinas of Diabetic Rats
Current Molecular Medicine Selective Serotonin Reuptake Inhibitors in Pregnancy
Current Medicinal Chemistry The Effectiveness of Nurse- and Pharmacist-Directed Care in Diabetes Disease Management:A Narrative Review
Current Diabetes Reviews The Potential Role of Angiotensin Converting Enzyme and Vasopeptidase Inhibitors in the Treatment of Diabetic Neuropathy
Current Drug Targets Tetrahydrobiopterin: A Vascular Redox Target to Improve Endothelial Function
Current Vascular Pharmacology Lipid-lowering Therapy in the Diabetic Foot: Seeing the Whole Iceberg and not Just the Tip
Current Vascular Pharmacology Therapeutic Strategies in the Treatment of Diabetic Nephropathy - a Translational Medicine Approach
Current Medicinal Chemistry Medical Implants as Delivery Platforms for Tissue Engineering and Regenerative Medicine Applications
Current Tissue Engineering (Discontinued) Cellular Membrane Microparticles: Potential Targets of Combinational Therapy for Vascular Disease
Current Vascular Pharmacology Towards Optimal Heart Failure Care: Couples-Oriented Strategies to Improve Patient Adherence and Health Outcomes
Current Cardiology Reviews Edible Mushrooms: Novel Medicinal Agents to Combat Metabolic Syndrome and Associated Diseases
Current Pharmaceutical Design The Tree of Sirtuins and the Garden of Cardiovascular Youth
Current Vascular Pharmacology Adiposity and Alzheimers Disease
Current Alzheimer Research Low-Dose Aspirin-Associated Upper and Mid Gastrointestinal Tract Damage and Gene Polymorphism
Current Pharmaceutical Design Exploring Old Drugs for the Treatment of Hematological Malignancies
Current Medicinal Chemistry Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets